Your Article Summary
See Latest ArticlesTreatment regimen extends survival for women with cervical cancer
National Cancer Institute, 07/02/09
Dueñas-González A et al. - In a trial to determine whether use of gemcitabine as part of initial treatment of locally advanced cervical cancer and part of therapy following primary treatment significantly improves survival for women with locally advanced cervical cancer, it was confirmed that this regimen does significantly improve survival for women with locally advanced cervical cancer.
Methods- More than 500 women with stage IIB to stage IVA cervical cancer participated.
- Pts were randomly assigned to the experimental treatment arm, which included cisplatin and gemcitabine with concurrent external-beam radiation therapy, followed by brachytherapy and adjuvant chemotherapy with gemcitabine and cisplatin.
- Women in the standard treatment group received cisplatin and concurrent external-beam radiation therapy followed by brachytherapy alone.
- Approximately 75% of women who received the experimental treatment did not experience progression of their disease 3 yrs after treatment, vs 65% of women who received standard treatment.
- Overall survival was improved, with 78% of women in the experimental treatment arm alive after 3 yrs vs 69% in the standard treatment arm.
- The research team had expected more toxicity with the addition of gemcitabine, and that is what they saw.
Related Articles
Macrophage migration inhibitory factor expression in cervical cancer
Journal of Cancer Research & Clinical Oncology, 11/23/09
Relevance Score: 71%
Circulating IL-1beta levels, polymorphisms of IL-1B, and risk of cervical cancer in Chinese women
Journal of Cancer Research & Clinical Oncology, 11/23/09
Relevance Score: 69%
Clinical Outcome of Tailored Adjuvant Postoperative Chemoradiotherapy in IB FIGO Stage Cervical Cancer
Anticancer Research, 11/13/09
Relevance Score: 69%
Transvaginal doppler sonography for assessment the response to radiotherapy in locally advanced squamous cervical cancer: a preliminary study
Archives of Medical Science, 11/03/09
Relevance Score: 69%
Screening for Cancer
MedLinePlus, 11/02/09
Relevance Score: 69%
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Epithelial-to-Mesenchymal Transition and Ovarian Tumor Progression Induced by Tissue Transglutaminase
Cancer Research, 12/20/09
Adult-Type Granulosa Cell Tumors and FOXL2 Mutation
Cancer Research, 12/20/09
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
BMC Cancer, 12/20/09